Pembrolizumab for Early Triple-Negative Breast Cancer

20202,951 citationsJournal Articlebronze Open Access

Authors

Peter Schmid · Queen Mary University of London

Javier Cortés · Instituto Oncológico Dr. Rosell

Lajos Pusztai · Yale Cancer Center

Heather L. McArthur · Cedars-Sinai Medical Center

Sherko Kümmel · Kliniken Essen-Mitte

Jonas Bergh · Karolinska University Hospital

Carsten Denkert

Abstract

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Breast Cancer Treatment Studies HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 9, pp. 810-821

DOI: 10.1056/nejmoa1910549

Field-Weighted Citation Impact: 136.48